The revenue decline and widening losses signal that the Australian prescription channel is not ramping fast enough to offset the cash burn. Despite the Nasdaq listing providing a liquidity cushion, the company is still pre-revenue at scale. Traders should watch for the next quarterly filing to see if new shipments to Australia resume or if the company diversifies into additional markets. The heavy investor relations spend ($1.17M) tied to the Nasdaq listing is a one-time cost, but the core operating loss remains substantial.
Price Chart
Executive Summary
Optimi Health Corp. filed its unaudited interim financial statements for the 9-month period ended June 30, 2026, reporting a sharp revenue decline to $239,700 (from $490,330 in the prior-year period) and a widened net loss of $5,552,091 (from $2,362,664). The revenue drop was attributed to sell-through of previously exported product in Australia rather than new shipments. The company completed a Nasdaq listing and $20.7M public offering, boosting cash to $13.1M, but operating cash burn was -$3.8M and the loss per share worsened to -$1.55 from -$0.74. The deteriorating fundamentals and heavy cash burn outweigh the liquidity benefit of the recent offering, making this a bearish read-through for the common equity despite the Nasdaq uplisting milestone.
Key Facts
- Revenue fell 51% YoY to $239,700 (9-month period ended June 30, 2026 vs $490,330)
- Net loss widened to $5,552,091 from $2,362,664; loss per share worsened to -$1.55 from -$0.74
- Operating cash flow was -$3,822,124 for the 9-month period
- Company raised $20,700,000 gross from a Nasdaq public offering, ending with $13,073,333 in cash
- Repaid $1,000,000 in loans during the period and settled $450,000 in convertible debt for 100,000 shares
- Subsequent to period end, repaid an additional $1,000,000 in loans and had 3,333 warrants expire unexercised
- Working capital improved to $5,879,279 positive; total shareholders' equity rose to $17,638,039
Financial Impact
Revenue decline of $250,630 (51% YoY) and net loss increase of $3,189,427 (135% YoY) for the 9-month period; cash burn from operations of -$3.8M
Risk Factors
- Revenue concentration on Australian Authorised Prescriber program with lumpy shipment timing
- High cash burn rate of -$3.8M from operations over 9 months despite $13.1M cash balance
- Related-party debt of $3M in convertible debentures at 15% interest maturing July 2026 creates refinancing risk
- Pre-revenue psychedelic sector with uncertain regulatory timelines for additional jurisdictions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005554 |
| Exhibit: exh_991.htm | 0001171843-26-005554 |
| Document: f6k_081426.htm | 0001171843-26-005554 |
| Document: 0001171843-26-005554-index-headers.html | 0001171843-26-005554 |
| Document: 0001171843-26-005554-index.html | 0001171843-26-005554 |
| Document: 0001171843-26-005554.txt | 0001171843-26-005554 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers